secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2022-11-09T23:59:59+00:00
Accession:  0001485003-22-000158
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio obtains final court approval for derivative lawsuit settlement
------------------------------------------------------------------------

- U.S. District Court for Massachusetts granted final approval on Nov 8, 2022 for settlement of consolidated derivative lawsuits.
- Settlement covers In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538, and Tang v. Sesen Bio, Inc., Case No. 2281-cv-00135.
- Company also disclosed securities class action settlement hearing set for Jan 23, 2023 in Southern District of New York.
- Previously, court granted preliminary approval on Sep 2, 2022; terms in Aug 30, 2022 8-K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000158/0001485003-22-000158-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500322000158/sesn-20221109.htm
  HTML page:      https://secwatch.observer/filing/0001485003-22-000158

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer